FDA News Highlights AJPB Week in Review
Top news of the week from The American Journal of Pharmacy Benefits.
5. Antipsychotic Drug Linked to Deaths in Parkinson's Patients
Reported deaths of Parkinson's patients treated with Acadia Pharmaceutical’s antipsychotic therapy pimavanserin (Nuplazid) has sparked concern. Read more.
4. FDA Restricts Sale of Bayer Permanent Contraception Device
FDA to limit distribution of Bayer’s Essure device to guarantee women considering permanent contraception are provided with adequate risk information. Read more.
3. FDA Approves Expanded Indications for Exparel
Bupivacaine liposome injectable suspension (Exparel) is the first long-acting, single-dose nerve block for patients undergoing upper extremity surgeries. Read more.
2. Acute Migraine Treatment Shows Positive Results in Trials
An acute treatment for migraines achieved both co-primary regulatory endpoints in 2 pivotal phase 3 trials. Read more.
1. FDA OKs Marketing for First AI Device for Diabetic Retinopathy Detection
Officials with the FDA have approved marketing of the first medical device to use artificial intelligence (AI) to detect notable eye disease diabetic retinopathy (DR) in adults with diabetes. Read more.
